Patent ID: 9696322
Date: 2017-07-04
CPC Classifications: G01N,G16B,G16H,Y02A

Claim:
1. A method for evaluating renal status in a subject not exhibiting AKI as measured by RIFLE I or F, comprising: determining a measured value for a urine Metalloproteinase inhibitor 2 (TIMP2) concentration; determining a measured value for a urine Insulin-like growth factor-binding protein 7 (IGFBP7) concentration; determining a measured value for a serum creatinine concentration; determining a measured value for urine output; correlating the assay result to a risk of future AKI in the subject, wherein said correlation step comprises (i) classifying the subject as at a first risk of future AKI if the serum creatinine value is greater than or equal to 0.3 mg/dL or increased to greater than or equal to 150% (1.5-fold) of a baseline serum creatinine value for the subject, (ii) classifying the subject as at a second risk of future AKI if the urine output value is less than 0.5 mL/kg per hour for more than 6 hours, (iii) classifying the subject as at a third risk of future AKI that is greater than the first and second risks if the subject is classified at both the first risk and the second risk; and (iv) classifying the subject as at a fourth risk of future AKI that is greater than the first, second, and third risks if the subject is classified at the third risk and product of the Insulin-like growth factor-binding protein 7 value and the Metalloproteinase inhibitor 2 value is above a predetermined threshold determined from a population study to indicate an increased risk of future AKI.